COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Review
Grant support
29957
Cancer Research UK - United Kingdom
PubMed
34756169
PubMed Central
PMC8553271
DOI
10.1016/s2352-3026(21)00278-7
PII: S2352-3026(21)00278-7
Knihovny.cz E-resources
- MeSH
- COVID-19 prevention & control MeSH
- Consensus MeSH
- Humans MeSH
- Multiple Myeloma complications drug therapy immunology MeSH
- SARS-CoV-2 MeSH
- Practice Guidelines as Topic standards MeSH
- Vaccination MeSH
- COVID-19 Vaccines administration & dosage MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- COVID-19 Vaccines MeSH
Patients with multiple myeloma frequently present with substantial immune impairment and an increased risk for infections and infection-related mortality. The risk for infection with SARS-CoV-2 virus and resulting mortality is also increased, emphasising the importance of protecting patients by vaccination. Available data in patients with multiple myeloma suggest a suboptimal anti-SARS-CoV-2 immune response, meaning a proportion of patients are unprotected. Factors associated with poor response are uncontrolled disease, immunosuppression, concomitant therapy, more lines of therapy, and CD38 antibody-directed and B-cell maturation antigen-directed therapy. These facts suggest that monitoring the immune response to vaccination in patients with multiple myeloma might provide guidance for clinical management, such as administration of additional doses of the same or another vaccine, or even temporary treatment discontinuation, if possible. In those who do not exhibit a good response, prophylactic treatment with neutralising monoclonal antibody cocktails might be considered. In patients deficient of a SARS-CoV-2 immune response, adherence to measures for infection risk reduction is particularly recommended. This consensus was generated by members of the European Multiple Myeloma Network and some external experts. The panel members convened in virtual meetings and conducted an extensive literature research and evaluated recently published data and work presented at meetings, as well as findings from their own studies. The outcome of the discussions on establishing consensus recommendations for COVID-19 vaccination in patients with multiple myeloma was condensed into this Review.
CHU Poitiers Poitiers France; Inserm Poitiers France
Clínica Universidad de Navarra CIMA CIBERONC IDISNA Pamplona Spain
Department of Hematology Amsterdam UMC VU University Amsterdam Netherlands
Department of Hematology Ankara University Ankara Turkey
Department of Hematology CHU de Liège Liège Belgium
Department of Hematology University hospital Hotel Dieu Nantes France
Department of Internal Medicine 2 University Hospital Würzburg Würzburg Germany
Department of Oncology and Hematology Kantonsspital St Gallen St Gallen Switzerland
Erasmus Medical Center Cancer Institute Erasmus University Rotterdam Rotterdam Netherlands
Institut Universitaire du Cancer de Toulouse Oncopole Toulouse France
Institute of Cancer Research London UK; Royal Marsden Hospital London UK
Leeds Institute of Clinical Trial Research University of Leeds Leeds UK
Leuven Cancer Institute Leuven Belgium
Oslo Myeloma Center Oslo University Hospital Oslo Norway
Universitätsklinikum Hamburg Eppendorf 2 Medizinische Klinik und Poliklinik Hamburg Germany
University of Lille CHU Lille Service des Maladies du Sang Lille France
See more in PubMed
Kristinsson SY, Tang M, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012;97:854–858. PubMed PMC
Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107–113. PubMed PMC
Ludwig H, Meckl A, Engelhardt M. Compliance with recommendations of vaccination among myeloma patients: a real world experience. HemaSphere. 2021;5:e597. PubMed PMC
Suen H, Brown R, Yang S, et al. Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia. 2016;30:1716–1724. PubMed
Zelle-Rieser C, Thangavadivel S, Biedermann R, et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016;9:116. PubMed PMC
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733. PubMed PMC
Chari A, Samur MK, Martinez-Lopez J, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136:3033–3040. PubMed PMC
Martínez-López J, Mateos MV, Encinas C, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020;10:103. PubMed PMC
Wang B, Van Oekelen O, Mouhieddine TH, et al. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol. 2020;13:94. PubMed PMC
Hultcrantz M, Richter J, Rosenbaum C, et al. COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers. Blood Cancer Discov. 2020;1:234–243. PubMed PMC
Cook G, John Ashcroft A, Pratt G, et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol. 2020;190:e83–e86. PubMed PMC
Engelhardt M, Shoumariyeh K, Rösner A, et al. Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. Haematologica. 2020;105:2872–2878. PubMed PMC
Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–2892. PubMed PMC
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416. PubMed PMC
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603–2615. PubMed PMC
European Medicines Agency Summary of Product Characteristics. 2021. https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-janssen-eparproduct-information_en.pdf
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. PubMed PMC
Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 COVID-19 vaccine. N Engl J Med. 2021;385:1172–1183. PubMed PMC
Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671–681. PubMed PMC
Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213–222. PubMed PMC
Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326:35–45. PubMed PMC
Centers for Disease Control and Prevention COVID-19 Vaccines for Moderately to Severely Immunocompromised People. 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html
Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020;369:806–811. PubMed PMC
Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184:476–488. PubMed PMC
Widge AT, Rouphael NG, Jackson LA, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384:80–82. PubMed PMC
Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. PubMed PMC
Sahin U, Muik A, Vogler I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595:572–577. PubMed
Krammer F, Srivastava K, Alshammary H, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384:1372–1374. PubMed PMC
Doria-Rose N, Suthar MS, Makowski M, et al. antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19. N Engl J Med. 2021;384:2259–2261. PubMed PMC
Jalkanen P, Kolehmainen P, Häkkinen HK, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun. 2021;12 PubMed PMC
Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276–280. PubMed
Bernal J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385:585–594. PubMed PMC
Gallagher KME, Leick MB, Larson RC, et al. SARS-CoV-2 T-cell immunity to variants of concern following vaccination. bioRxiv. 2021 doi: 10.1101/2021.05.03.442455. published online May 3. (preprint). DOI
Karlsson J, Andréasson B, Kondori N, et al. Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin Vaccine Immunol. 2011;18:969–977. PubMed PMC
Gustafson CE, Kim C, Weyand CM, Goronzy JJ. Influence of immune aging on vaccine responses. J Allergy Clin Immunol. 2020;145:1309–1321. PubMed PMC
Terpos E, Trougakos IP, Gavriatopoulou M, et al. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021;137:3674–3676. PubMed PMC
Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021;11:138. PubMed PMC
Bird S, Panopoulou A, Shea RL, et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet Haematol. 2021;8:e389–e392. PubMed PMC
Pimpinelli F, Marchesi F, Piaggio G, et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. J Hematol Oncol. 2021;14:81. PubMed PMC
Van Oekelen O, Gleason CR, Agte S, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021;39:1028–1030. PubMed PMC
Passamonti F, Romano A, Salvini M, et al. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. Br J Haematol. 2021 doi: 10.1111/bjh.17704. published online July 16. PubMed DOI PMC
Vibholm LK, Nielsen SSF, Pahus MH, et al. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine. 2021;64 PubMed PMC
Zimmer K. A Guide to Emerging SARS-CoV-2 variants. 2021. https://www.the-scientist.com/news-opinion/a-guide-to-emerging-sars-cov-2-variants-68387
Davies NG, Jarvis CH, Edmunds WJ, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.72. Nature. 2021;593:270–274. PubMed PMC
Centers for Disease Control and Prevention Interim Guidelines for COVID-19 Antibody Testing. 2021. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html
Edara VV, Pinsky BA, Suthar MS, et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. N Engl J Med. 2021;385:664–666. PubMed PMC
Collier DA, De Marco A, Ferreira I, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593:136–141. PubMed PMC
Ramanathan M, Ferguson ID, Miao W, Khavari PA. SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants bind human ACE2 with increased affinity. Lancet Infect Dis. 2021;21 PubMed PMC
Edara VV, Norwood C, Floyd K, et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe. 2021;29:516–521. PubMed PMC
Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385:187–189. PubMed PMC
Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384:1885–1898. PubMed PMC
Alter G, Yu J, Liu J, et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021;596:268–272. PubMed PMC
Mahase E. COVID-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ. 2021;372:n296. PubMed
Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 COVID-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384:1899–1909. PubMed PMC
Wang P, Casner RG, Nair MS, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 2021;29:747–751. PubMed PMC
Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum. N Engl J Med. 2021;384:1466–1468. PubMed PMC
Shrotri M, Krutikov M, Palmer T, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00289-9. published online June 23. PubMed DOI PMC
Callaway E. Mix-and-match COVID vaccines trigger potent immune response. Nature. 2021;593:491. PubMed
Precision Vaccine VLA2001 COVID-19 vaccine. 2021. https://www.precisionvaccinations.com/vaccines/vla2001-covid-19-vaccine
Démoulins T, Englezou PC, Milona P, et al. Self-replicating RNA vaccine delivery to dendritic cells. Methods Mol Biol. 2017;1499:37–75. PubMed
Frerichs KA, Bosman PWC, van Velzen JF, et al. Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. Haematologica. 2020;105:e302–e306. PubMed PMC
Nahi H, Chrobok M, Gran C, et al. Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma. PLoS One. 2019;14 PubMed PMC
Noonan K, Rudraraju L, Ferguson A, et al. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res. 2012;18:1426–1434. PubMed PMC
Borhani K, Bamdad T, Hashempour T. Lenalidomide acts as an adjuvant for HCV DNA vaccine. Int Immunopharmacol. 2017;48:231–240. PubMed
Hurt AC, Wheatley AK. Neutralizing antibody therapeutics for COVID-19. Viruses. 2021;13:628. PubMed PMC
Cohen MS, Nirula A, Mulligan MJ, et al. Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial. JAMA. 2021;326:46–55. PubMed PMC
O'Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. N Engl J Med. 2021;385:1184–1195. PubMed PMC
Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021 doi: 10.1056/NEJMoa2108163. published online September 29. PubMed DOI PMC
An EUA for bamlanivimab and etesevimab for COVID-19. Med Lett Drugs Ther. 2021;63:49–50. PubMed
Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med. 2021;384:610–618. PubMed PMC
Kenig A, Ishay Y, Kharouf F, Rubin L. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products. Clin Immunol. 2021;227 PubMed PMC
Abani O, Abbas A, Abbas F, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397:2049–2059. PubMed PMC
Singh P, Dhalaria P, Ghosh S, et al. Strategies to overcome vaccine hesitancy. Syst Rev. 2020 doi: 10.21203/rs.3.rs-26923/v1. published online May 20. (preprint). PubMed DOI PMC
de Figueiredo A, Simas C, Karafillakis E, Paterson P, Larson HJ. Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study. Lancet. 2020;396:898–908. PubMed PMC
Racey CS, Donken R, Porter I, et al. Intentions of public school teachers in British Columbia, Canada to receive a COVID-19 vaccine. Vaccine X. 2021;8 PubMed PMC
Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med. 2021;384:643–649. PubMed PMC
Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21:939–949. PubMed PMC
European Medicines Agency Vaxzevria (previously COVID-19 Vaccine AstraZeneca) 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca
Johnston MS, Galan A, Watsky KL, Little AJ. Delayed localized hypersensitivity reactions to the moderna COVID-19 vaccine: a case series. JAMA Dermatol. 2021;157:716–720. PubMed PMC
Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;9:1423–1437. PubMed PMC
Cines DB, Bussel JB. SARS-CoV-2 Vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med. 2021;384:2254–2256. PubMed PMC
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384:2092–2101. PubMed PMC
Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384:2202–2211. PubMed PMC
Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. 2021;384:2187–2201. PubMed PMC
Trimboli M, Zoleo P, Arabia G, Gambardella A. Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine. Neurol Sci. 2021;42:4401–4402. PubMed PMC
Choi G-J, Baek SH, Kim J, et al. Fatal systemic capillary leak syndrome after SARS-CoV-2 vaccination in patient with multiple myeloma. Emerg Infect Dis. 2021;27:2973–2975. PubMed PMC
International Myeloma Society Recommendations for anti-COVID-19 vaccination in patients with multiple myeloma (MM) and related conditions, AL amyloidosis and other monoclonal gammopathies of clinical significance. 2021. https://myeloma.wpengine.com/wp-content/uploads/2021/03/PM-COVID-vaccination-in-MM-guidelines-The-Final.pdf
US Food and Drug Administration Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals. 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised
Eurpoean Pharmaceutical Review FDA approves emergency use of REGEN-COV™ for COVID-19 prevention. 2021. https://www.europeanpharmaceuticalreview.com/news/159504/fda-approve-emergency-use-of-regen-covtm-for-covid-19-prevention/
US Food and Drug Administration FDA authorizes bamlanivimab and etesevimab monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19. 2021. https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-bamlanivimab-and-etesevimab-monoclonal-antibody-therapy-post-exposure-prophylaxis
